# CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）

> **NCT07432178** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 2288 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Dalpiciclib+AI ± OFS
- **DRUG:** TC (Docetaxel + Cyclophosphamide) × 4 cycles- endocrine therapy

## Key facts

- **NCT ID:** NCT07432178
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2031-03-31
- **Final completion:** 2034-03-31
- **Target enrollment:** 2288 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07432178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07432178, "CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07432178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*